Herceptin as a single agent in patients with HER2 overexpressing metastatic breast cancer.
- Author:
Tao WANG
1
;
Ze-fei JIANG
;
San-tai SONG
;
Xiao-qing LIU
;
Jing-xin YU
;
Fang LIU
;
Min YAN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antibodies, Monoclonal; administration & dosage; adverse effects; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; administration & dosage; adverse effects; Bone Neoplasms; drug therapy; secondary; Breast Neoplasms; drug therapy; metabolism; pathology; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fever; chemically induced; Heart Diseases; chemically induced; Humans; Middle Aged; Neoplasm Recurrence, Local; drug therapy; metabolism; Receptor, ErbB-2; metabolism; Soft Tissue Neoplasms; drug therapy; secondary; Trastuzumab
- From: Chinese Journal of Oncology 2004;26(7):430-432
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and adverse reactions of Herceptin as a single agent in patients with HER2 overexpressing metastatic breast cancer.
METHODSThere were two kinds of therapy protocol. One was loading-dose of 4 mg/kg intravenously, followed by a 2 mg/kg maintenance dose of weekly intervals. The other was loading-dose of 8 mg/kg, followed by 6 mg/kg of every three weeks intervals.
RESULTSAmong 20 patients with evaluated efficacy, there was no complete response, 5 patients (25.0%) showed partial response (PR), 5 (25.0%) stable disease (SD) and 10 (50.0%) progressive disease (PD). Of 22 patients, the overall response rate was 22.7%. The median time of disease progression and treatment failure was 6 weeks and 6.5 weeks, respectively. The most common adverse reactions were fever and chill. Cardiac symptoms could be seen in some patients.
CONCLUSIONHerceptin is an active agent for the patients with HER2 overexpressing metastatic breast cancer and the adverse events are well tolerated.
